Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA429908
Max Phase: Preclinical
Molecular Formula: C103H117N23O24
Molecular Weight: 2061.21
Molecule Type: Protein
Associated Items:
ID: ALA429908
Max Phase: Preclinical
Molecular Formula: C103H117N23O24
Molecular Weight: 2061.21
Molecule Type: Protein
Associated Items:
Canonical SMILES: C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(N)=O)NC(=O)CN)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
Standard InChI: InChI=1S/C103H117N23O24/c1-54(113-101(147)89(55(2)127)125-87(133)52-111-90(136)78(43-63-51-107-53-112-63)121-96(142)77(41-61-49-109-70-24-13-10-21-67(61)70)119-97(143)79(44-84(105)130)114-86(132)47-104)102(148)126-35-15-26-83(126)100(146)123-81(46-88(134)135)99(145)120-76(40-60-48-108-69-23-12-9-20-66(60)69)95(141)117-72(36-56-16-5-3-6-17-56)91(137)115-73(37-57-18-7-4-8-19-57)93(139)122-80(45-85(106)131)98(144)118-74(38-58-27-31-64(128)32-28-58)92(138)116-75(39-59-29-33-65(129)34-30-59)94(140)124-82(103(149)150)42-62-50-110-71-25-14-11-22-68(62)71/h3-14,16-25,27-34,48-51,53-55,72-83,89,108-110,127-129H,15,26,35-47,52,104H2,1-2H3,(H2,105,130)(H2,106,131)(H,107,112)(H,111,136)(H,113,147)(H,114,132)(H,115,137)(H,116,138)(H,117,141)(H,118,144)(H,119,143)(H,120,145)(H,121,142)(H,122,139)(H,123,146)(H,124,140)(H,125,133)(H,134,135)(H,149,150)/t54-,55+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
Standard InChI Key: ZUENRBCVCNXGQC-RYIFUXPHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2061.21 | Molecular Weight (Monoisotopic): 2059.8642 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Suzawa T, Shibata K, Tanaka T, Matsuda Y, Yamasaki M. (1997) RES-701-1/endothelin-1 hybrid peptide having a potent binding activity for type B receptor, 7 (13): [10.1016/S0960-894X(97)00296-5] |
Source(1):